Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.10.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2016 $ 32,090 $ 3 $ 156,390 $ (124,303)
Balance (in shares) at Dec. 31, 2016   2,966,904    
Issuance common stock for cash, net of issuance costs of $695 5,849 $ 2 5,847  
Issuance common stock for cash, net of issuance costs of $695 (in shares)   1,639,825    
Stock-based compensation [1] 2,393 $ 0 2,393  
Stock-based compensation (in shares) [1]   181,936    
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition [2] 675 $ 0 675  
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (in shares) [2]   101,243    
Issuance of common stock in connection with the contingent consideration of the Choice Therapeutics acquisition [3] 500 $ 0 500  
Issuance of common stock in connection with the contingent consideration of the Choice Therapeutics acquisition (in shares) [3]   131,579    
Payment of withholding taxes related to stock-based employee compensation (133) $ 0 (133)  
Payment of withholding taxes related to stock-based employee compensation (in shares)   (35,453)    
Net loss (25,707)     (25,707)
Balance at Dec. 31, 2017 15,667 $ 5 165,672 (150,010)
Balance (in shares) at Dec. 31, 2017   4,986,034    
Stock-based compensation 1,004 $ 0 1,004  
Stock-based compensation (in shares)   20,000    
Payment of withholding taxes related to stock-based employee compensation (2) $ 0 (2)  
Payment of withholding taxes related to stock-based employee compensation (in shares)   (823)    
Net loss (8,417)     (8,417)
Balance at Dec. 31, 2018 $ 8,252 $ 5 $ 166,674 $ (158,427)
Balance (in shares) at Dec. 31, 2018   5,005,211    
[1] Includes $374,000 that was part of accrued expenses as of December 31, 2016, which was credited to equity upon the issuance of 60,000 restricted common shares during the year ended December 31, 2017.
[2] Includes $675,000 that was part of contingent consideration as of December 31, 2016, which was credited to equity upon the issuance of 101,243 common shares during the year ended December 31, 2017.
[3] Includes $500,000 that was part of contingent consideration as of December 31, 2016, which was credited to equity upon the issuance of 131,579 common shares during the year ended December 31, 2017.